Olysio: further oral treatment option for chronic hepatitis C

The launch of Olysio (simeprevir) provides a further oral treatment for combination therapy in hepatitis C and can be used without concomitant interferon.

Olysio (simeprevir) is a new oral directly-acting antiviral for the treatment of hepatitis C
Olysio (simeprevir) is a new oral directly-acting antiviral for the treatment of hepatitis C

Simeprevir is a direct-acting hepatitis C virus (HCV) NS3/4A serine protease inhibitor that prevents viral replication. 

Simeprevir can be used to treat patients infected with viral genotypes 1 and 4. It is taken in combination with peginterferon alfa and ribavirin in treatment-naive patients, patients who have relapsed following prior therapy and those who have not responded to previous treatment (including partial and null responders). It can also be given in combination with sofosbuvir (Sovaldi) in all patients with HCV genotype 1 or 4 regardless of prior therapy when interferon cannot be used or is not tolerated; ribavirin can be added to this two-drug regimen based on a clinical assessment of the individual patient.

Before treating patients with HCV genotype 1a, the manufacturer recommends testing the virus for the NS3 Q80K polymorphism as the efficacy of simeprevir is substantially reduced in the presence of this variant and alternative therapy should be considered.

Simeprevir was investigated in combination with peginterferon and ribavirin in the QUEST-1, QUEST-2 and PROMISE phase III clinical studies. All three studies met their primary endpoints, namely that the virological response rates were significantly higher in patients who received simeprevir plus peginterferon and ribavirin than in patients who received peginterferon and ribavirin alone.

Approval for the combination of simeprevir and sofosbuvir (with and without ribavirin) was based on positive data from the phase II COSMOS study.

Dr Andrew Ustianowski, Chair of the British Viral Hepatitis Group and Consultant in Infectious Diseases at North Manchester General Hospital welcomed simeprevir as "a well-tolerated and efficacious addition to our therapies against hepatitis C".

View Olysio drug record

Further information: Janssen-Cilag

Follow MIMS on Twitter

Sign up for MIMS bulletins


Read these next

AbbVie launches two new oral treatments for hepatitis C

AbbVie launches two new oral treatments for hepatitis C

Exviera (dasabuvir) and Viekirax (ombitasvir/paritaprevir/ritonavir)...

Harvoni: single-tablet option in hepatitis C

Harvoni: single-tablet option in hepatitis C

Gilead has launched Harvoni (ledipasvir/sofosbuvir),...

New oral hepatitis C treatment launched

New oral hepatitis C treatment launched

Daklinza (daclatasvir) is licensed in combination with...

Sovaldi: a new treatment option for chronic hepatitis C

Sovaldi: a new treatment option for chronic hepatitis C

Sovaldi (sofosbuvir) is a novel oral treatment for...

New hepatitis C drugs approved by NICE

New hepatitis C drugs approved by NICE

Following review by NICE, the protease inhibitors...


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.